AZNCF
Price
$141.40
Change
+$1.25 (+0.89%)
Updated
Jul 9 closing price
Capitalization
222.83B
NVS
Price
$123.71
Change
+$0.77 (+0.63%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
197.93B
7 days until earnings call
Interact to see
Advertisement

AZNCF vs NVS

Header iconAZNCF vs NVS Comparison
Open Charts AZNCF vs NVSBanner chart's image
AstraZeneca
Price$141.40
Change+$1.25 (+0.89%)
Volume$674
Capitalization222.83B
Novartis AG
Price$123.71
Change+$0.77 (+0.63%)
Volume$16.68K
Capitalization197.93B
AZNCF vs NVS Comparison Chart in %
Loading...
AZNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AZNCF vs. NVS commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZNCF is a Hold and NVS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (AZNCF: $141.40 vs. NVS: $123.73)
Brand notoriety: AZNCF and NVS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZNCF: 12% vs. NVS: 117%
Market capitalization -- AZNCF: $222.83B vs. NVS: $197.93B
AZNCF [@Pharmaceuticals: Major] is valued at $222.83B. NVS’s [@Pharmaceuticals: Major] market capitalization is $197.93B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZNCF’s FA Score shows that 1 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • AZNCF’s FA Score: 1 green, 4 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, NVS is a better buy in the long-term than AZNCF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZNCF’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).

  • AZNCF’s TA Score: 4 bullish, 6 bearish.
  • NVS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NVS is a better buy in the short-term than AZNCF.

Price Growth

AZNCF (@Pharmaceuticals: Major) experienced а +0.51% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.39%. For the same industry, the average monthly price growth was +1.04%, and the average quarterly price growth was +11.01%.

Reported Earning Dates

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.39% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AZNCF($223B) has a higher market cap than NVS($198B). AZNCF has higher P/E ratio than NVS: AZNCF (36.10) vs NVS (23.38). NVS YTD gains are higher at: 31.728 vs. AZNCF (8.769). NVS has higher annual earnings (EBITDA): 18.3B vs. AZNCF (12.9B). NVS has more cash in the bank: 14B vs. AZNCF (5.81B). NVS has less debt than AZNCF: NVS (26.3B) vs AZNCF (29.8B). NVS (46.7B) and AZNCF (44.5B) have equivalent revenues.
AZNCFNVSAZNCF / NVS
Capitalization223B198B113%
EBITDA12.9B18.3B70%
Gain YTD8.76931.72828%
P/E Ratio36.1023.38154%
Revenue44.5B46.7B95%
Total Cash5.81B14B42%
Total Debt29.8B26.3B113%
FUNDAMENTALS RATINGS
AZNCF vs NVS: Fundamental Ratings
AZNCF
NVS
OUTLOOK RATING
1..100
1866
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
20
Undervalued
PROFIT vs RISK RATING
1..100
5113
SMR RATING
1..100
4629
PRICE GROWTH RATING
1..100
5846
P/E GROWTH RATING
1..100
8281
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (20) in the Pharmaceuticals Major industry is in the same range as AZNCF (24) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.

NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZNCF (51) in the null industry. This means that NVS’s stock grew somewhat faster than AZNCF’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is in the same range as AZNCF (46) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.

NVS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as AZNCF (58) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.

NVS's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as AZNCF (82) in the null industry. This means that NVS’s stock grew similarly to AZNCF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNCFNVS
RSI
ODDS (%)
Bearish Trend 1 day ago
43%
Bearish Trend 2 days ago
53%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 2 days ago
35%
Momentum
ODDS (%)
Bearish Trend 1 day ago
59%
Bullish Trend 2 days ago
49%
MACD
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 2 days ago
56%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
56%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
57%
Bullish Trend 2 days ago
45%
Advances
ODDS (%)
Bullish Trend 9 days ago
65%
Bullish Trend 9 days ago
49%
Declines
ODDS (%)
N/A
Bearish Trend 21 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 2 days ago
43%
Aroon
ODDS (%)
Bullish Trend 1 day ago
56%
Bullish Trend 2 days ago
40%
View a ticker or compare two or three
Interact to see
Advertisement
AZNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RDHL2.130.04
+1.91%
Redhill Biopharma Ltd
MTB204.053.67
+1.83%
M&T Bank Corp
SR74.560.61
+0.82%
Spire
CPSS10.070.04
+0.40%
Consumer Portfolio Services
ABL5.20N/A
N/A
Abacus Global Management Inc

AZNCF and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZNCF has been loosely correlated with AZN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZNCF jumps, then AZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZNCF
1D Price
Change %
AZNCF100%
N/A
AZN - AZNCF
48%
Loosely correlated
+1.40%
NVS - AZNCF
24%
Poorly correlated
+0.64%
SNY - AZNCF
23%
Poorly correlated
+1.04%
MRK - AZNCF
19%
Poorly correlated
+0.37%
BAYRY - AZNCF
18%
Poorly correlated
+1.00%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.64%
GSK - NVS
65%
Loosely correlated
+1.38%
AZN - NVS
63%
Loosely correlated
+1.40%
JNJ - NVS
55%
Loosely correlated
+0.90%
PFE - NVS
54%
Loosely correlated
+0.86%
AMGN - NVS
48%
Loosely correlated
+1.30%
More